Cluster Headache

Quick Reference

Critical Alerts

• Most severe primary headache disorder: Described as "suicide headache" due to excruciating pain intensity
• High-flow oxygen (100%, 12-15 L/min) is first-line acute treatment: Achieves ~80% response rate within 15 minutes
• Subcutaneous sumatriptan 6 mg is most effective triptan formulation: Rapid onset of action
• Attacks are brief (15-180 min) but recurrent: 1-8 attacks per day during cluster periods
• Restlessness/agitation is diagnostic hallmark: Unlike migraine where patients prefer stillness
• Rule out secondary causes on first presentation: Neuroimaging mandatory for atypical features
• Verapamil requires ECG monitoring: Risk of PR interval prolongation and heart block at high doses (480-960 mg/day)

Classic Presentation

Emergency Treatments

---

Definition

Overview

Cluster headache is a primary headache disorder classified as a trigeminal autonomic cephalalgia (TAC), characterized by severe, strictly unilateral headaches with prominent ipsilateral cranial autonomic features and a distinctive pattern of circadian and circannual periodicity. [1,2] It is widely described as the most painful condition a human can experience, earning the colloquial term "suicide headache." [3] The disorder is defined by recurrent attacks of excruciating periorbital pain lasting 15-180 minutes, occurring with remarkable regularity (often at the same time each day), accompanied by ipsilateral autonomic symptoms such as lacrimation, conjunctival injection, and nasal congestion. [4]

The pathophysiology involves activation of the trigeminal-autonomic reflex and hypothalamic dysfunction, explaining both the pain characteristics and the striking temporal patterns. [5,6] Unlike migraine, where patients seek quiet, dark environments and remain still, cluster headache patients are characteristically restless and agitated during attacks, often pacing or rocking. [7]

Classification

By Periodicity (ICHD-3 Criteria):

Note: Chronic cluster headache definition changed in ICHD-3 from remission less than 1 month to less than 3 months. [8]

Epidemiology

Prevalence and Incidence:

• Global prevalence: 0.05-0.1% (approximately 1 in 1,000 population) [9,10]
• Lifetime prevalence: 124 per 100,000 (recent population-based studies suggest lower than historical estimates) [11]
• Annual incidence: 2-10 per 100,000 person-years [12]
• Distribution: 80-90% episodic, 10-20% chronic [13]

Demographics:

• Male predominance: Historically 3-4:1, but narrowing to 2-2.5:1 in recent studies [14,15]
  • The decreasing male-to-female ratio may reflect changing diagnostic awareness, lifestyle factors, or hormonal influences
  • In chronic cluster headache and late-onset cases, female predominance has been reported [16]
• Age of onset: Mean 20-40 years (range: childhood to elderly) [17]
  • "Peak onset: Third decade of life"
  • 5% onset before age 18
  • "Late-onset (> 50 years): 10-15% of cases"
• Familial clustering: 5-20% have affected first-degree relative (suggesting genetic component) [18]

Geographic and Ethnic Variation:

• Lower prevalence reported in Asian populations compared to Caucasian populations
• Clinical features remarkably consistent across different ethnicities, though attack frequency and bout characteristics show regional variability [19]

Etiology and Risk Factors

Pathophysiological Mechanisms:

1. Hypothalamic Dysfunction [5,20]

   • Posterior hypothalamic gray matter activation demonstrated on PET and fMRI during attacks
   • Hypothalamus acts as circadian pacemaker, explaining periodicity
   • Neuroendocrine disturbances (melatonin, cortisol, testosterone) support hypothalamic involvement
   • Suprachiasmatic nucleus regulates circadian and circannual rhythms

2. Trigeminal-Autonomic Reflex Activation [21]

   • Trigeminal nerve afferents (pain)
   • Parasympathetic efferents via superior salivatory nucleus (autonomic features)
   • Activation of this reflex produces characteristic ipsilateral autonomic symptoms
   • Sympathetic dysfunction (partial Horner's syndrome: ptosis, miosis)

3. Neurovascular Inflammation

   • Activation of trigeminovascular system
   • Release of vasoactive neuropeptides: CGRP, VIP, PACAP
   • Neurogenic inflammation and vasodilation

4. Genetic Factors [22]

   • Eight genetic loci identified through genome-wide association studies (GWAS)
   • Familial clustering in 5-20%
   • No single Mendelian inheritance pattern; likely polygenic

Triggers During Cluster Period:

Note: Triggers typically only provoke attacks during active cluster periods, not during remission.

Risk Factors:

• Smoking: Strong association (65-85% of cluster headache patients are smokers or ex-smokers) [23]
• Head trauma: May precipitate onset in some cases
• Male sex (though ratio narrowing)
• Family history

---

Pathophysiology

Molecular and Cellular Mechanisms

Hypothalamic Generator [5,24]

• Posterior hypothalamic gray matter serves as the "cluster generator"
• Functional neuroimaging (PET, fMRI) shows activation during attacks but not between attacks
• Hypothalamic nuclei regulate:
  • Circadian rhythms (explaining same-time-each-day attacks)
  • Circannual rhythms (explaining seasonal clustering)
  • Autonomic outflow
  • Pain modulation

Trigeminal-Autonomic Reflex Pathway [21,25]

1. Afferent limb: Trigeminal nerve (ophthalmic division V1)
   • Activation causes severe periorbital/temporal pain
   • Peripheral and central sensitization
2. Central processing: Trigeminal nucleus caudalis and superior salivatory nucleus
3. Efferent limb:
   • Parasympathetic: Superior salivatory nucleus → greater petrosal nerve → sphenopalatine ganglion → cranial vasculature
     • Produces: Lacrimation, conjunctival injection, rhinorrhea, nasal congestion
   • Sympathetic dysfunction: Ptosis and miosis (partial Horner's syndrome)
     • Oculosympathetic pathway disruption

Neuropeptide Involvement

• CGRP (Calcitonin Gene-Related Peptide): Elevated during attacks; powerful vasodilator [26]
  • CGRP antagonism (monoclonal antibodies) effective in episodic cluster headache prevention
• VIP (Vasoactive Intestinal Peptide): Elevated; parasympathetic marker
• PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide): Elevated during attacks

Chronobiological Mechanisms [27]

• Circadian periodicity: Attacks at predictable times (often nocturnal)
• Circannual periodicity: Cluster periods in spring/autumn in many patients
• Disrupted melatonin secretion: Low levels during cluster periods
• Disrupted cortisol and testosterone rhythms

Why Patients Are Restless

The agitation and restlessness observed in cluster headache (unlike migraine) may result from:

• Severe pain intensity overwhelming ability to remain still
• Hypothalamic activation influencing arousal and motor behavior
• Autonomic activation creating sense of agitation
• Differentiating feature: Migraine patients prefer quiet, dark, still environments; cluster headache patients pace, rock, bang head [28]

---

Clinical Presentation

Symptoms

Headache Characteristics:

Cranial Autonomic Features (Ipsilateral to Pain) [4,29]:

At least ONE autonomic feature must be present for diagnosis (or patient exhibits restlessness/agitation). [30]

Behavioral Features During Attack:

• Restlessness/agitation: 90-95% [7]
  • Pacing, rocking, cannot sit or lie still
  • May bang head against wall or press on painful area
  • Inability to remain motionless (cardinal differentiating feature from migraine)
• Sense of impending attack: Some patients report premonitory symptoms 10-30 minutes before

Associated Symptoms (Less Common than Migraine):

• Photophobia/phonophobia: 30-50% (less prominent than migraine)
• Nausea: 40-50%
• Aura: Very rare (less than 5%); when present, suggests hemiplegic cluster headache variant

Cluster Period Characteristics:

• Duration: 2 weeks to 12 months (median 6-12 weeks)
• Frequency: Variable; some patients have annual clusters, others every few years
• Seasonal pattern: 40-50% report clustering in spring or autumn
• Remission period (episodic): ≥3 months pain-free

Pre-Cluster and Pre-Attack Symptoms [31]:

• Pre-cluster prodrome: Milder ipsilateral head discomfort days before cluster onset
• Pre-attack warning: Ipsilateral discomfort, autonomic symptoms 10-30 minutes before

Post-Attack (Postictal) Symptoms:

• Exhaustion, fatigue
• Residual mild ipsilateral head discomfort
• Autonomic symptoms typically resolve with pain cessation

History

Key Questions for Diagnosis:

1. Pain Characteristics:

   • Where is the headache located? (Strictly unilateral, periorbital/temporal?)
   • How would you describe the pain? (Quality, intensity 0-10)
   • How long does each attack last? (15-180 min)
   • How quickly does the pain reach its peak? (Minutes)

2. Frequency and Pattern:

   • How many attacks do you have per day? (1-8)
   • Do attacks occur at the same time each day? (Circadian pattern)
   • Do you wake up with attacks at night? (Nocturnal attacks)
   • How long have you had this cluster of headaches? (Cluster duration)
   • Have you had prior episodes like this? When? (Episodic vs chronic)

3. Autonomic Symptoms:

   • Do you have tearing, red eye, runny nose, or nasal congestion on the same side as the pain?
   • Do you notice eyelid drooping or pupil changes?
   • Is there facial sweating on the painful side?

4. Behavior During Attack:

   • What do you do during an attack? (Restless, pacing vs lying still)
   • Can you sit or lie still? (Inability to remain still is characteristic)

5. Triggers:

   • Does alcohol trigger attacks during these periods? (Most reliable trigger)
   • Any other triggers? (Sleep, strong odors, altitude)

6. Prior Treatment:

   • Have you tried oxygen or sumatriptan?
   • Any preventive medications (verapamil, lithium)?
   • Response to prior treatments?

7. Red Flags:

   • Is this your first-ever episode of these headaches? (Requires imaging)
   • Any fever, neck stiffness, vision changes, weakness, numbness?
   • Any change in headache pattern from previous clusters?

Physical Examination

During Attack:

Between Attacks (Interictal Period):

• Neurological examination: Typically completely normal
• Residual mild ptosis: May persist in some patients
• No focal neurological deficits (if present, consider secondary causes)

Red Flag Examination Findings (Suggest Secondary Causes):

• Fever
• Meningismus (neck stiffness)
• Papilledema (increased intracranial pressure)
• Focal neurological deficits (weakness, sensory loss, ataxia)
• Cranial nerve palsies (other than partial Horner's)
• Altered consciousness

---

Red Flags and Secondary Causes

When to Suspect Secondary Cluster Headache

Indications for Neuroimaging (MRI Brain with Contrast) [32]:

Secondary Causes of Cluster-Like Headache [33]:

• Vascular: Carotid/vertebral artery dissection, cavernous sinus thrombosis, AVM, aneurysm (especially posterior communicating artery)
• Structural: Pituitary tumor/apoplexy, meningioma, glioma, metastases
• Inflammatory: Granulomatosis with polyangiitis, sarcoidosis
• Infectious: Sinusitis (though usually bilateral and lacks autonomic features), orbital cellulitis
• Other: Acute angle-closure glaucoma, temporal arteritis

---

Differential Diagnosis

Other Trigeminal Autonomic Cephalalgias (TACs)

Other Severe Unilateral Headaches

---

Diagnostic Approach

Clinical Diagnosis

Cluster headache is a clinical diagnosis based on history and examination. [30]

ICHD-3 Diagnostic Criteria for Cluster Headache:

A. At least 5 attacks fulfilling criteria B-D

B. Severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15-180 minutes (when untreated)

C. Either or both of the following:

1. At least one of the following symptoms or signs, ipsilateral to the headache:
   • Conjunctival injection and/or lacrimation
   • Nasal congestion and/or rhinorrhea
   • Eyelid edema
   • Forehead and facial sweating
   • Miosis and/or ptosis
2. A sense of restlessness or agitation

D. Attacks have a frequency between one every other day to 8 per day for more than half the time when the disorder is active

E. Not better accounted for by another ICHD-3 diagnosis

Episodic vs Chronic Classification:

• Episodic: Attacks occur in periods lasting 7 days to 1 year, separated by pain-free periods ≥3 months
• Chronic: Attacks occur for > 1 year without remission, or with remissions lasting less than 3 months

Diagnostic Testing

Imaging:

MRI Brain with Contrast:

• Indications:

  • First presentation of cluster headache (to rule out secondary causes)
  • Atypical features (bilateral, > 3 hours duration, no autonomic features)
  • Focal neurological signs or symptoms
  • Age > 50 at onset
  • Treatment-refractory headache
  • Change in headache pattern from prior clusters

• Not routinely required if:

  • Established diagnosis of cluster headache
  • Typical features (unilateral, 15-180 min, autonomic features, circadian pattern)
  • Normal neurological examination
  • Good response to standard treatment

Laboratory Testing:

• Generally not required for typical cluster headache
• ESR and CRP: If age > 50, concern for giant cell arteritis
• Intraocular pressure (tonometry): If concern for acute angle-closure glaucoma

Other Investigations:

• ECG: Baseline before starting verapamil (to assess PR interval, QRS, heart rate)
• Indomethacin trial: If considering paroxysmal hemicrania or hemicrania continua (absolute response within 1-2 days)

---

Treatment

Principles of Management

Cluster headache treatment is multimodal and divided into: [34]

1. Acute (Abortive) Treatment: Terminate individual attacks
2. Transitional (Bridge) Therapy: Provide rapid relief while preventive therapy takes effect
3. Preventive (Prophylactic) Treatment: Reduce attack frequency and severity during cluster period
4. Lifestyle Modifications: Avoid triggers, maintain sleep hygiene

Treatment Goals:

• Rapid termination of acute attacks (within 15-30 minutes)
• Reduce attack frequency and severity
• Minimize disability and improve quality of life
• Prevent chronic transformation
• Avoid medication overuse

---

Acute (Abortive) Treatment

Goal: Terminate attack within 15-30 minutes

First-Line Acute Treatments

1. High-Flow Oxygen Therapy [35,36]

Level A Evidence (American Headache Society Guidelines)

Mechanism: Hypothesized to involve cerebral vasoconstriction, modulation of trigeminoautonomic reflex, and neurotransmitter effects. [37]

Advantages:

• No contraindications
• Safe in pregnancy, cardiovascular disease, elderly
• Can be used multiple times per day
• No medication overuse headache risk

Disadvantages:

• Requires prescription and home oxygen setup
• Oxygen tanks/concentrators may not be readily available
• Insurance coverage issues (especially in USA)
• Portability limitations

Prescription for Home Oxygen:

• "100% oxygen at 12-15 L/min via non-rebreather mask for 15-20 minutes as needed for cluster headache attacks"
• Provide letter of medical necessity for insurance

Demand-Valve Oxygen: Higher flow rates (up to 40 L/min); some evidence for superiority but less widely available.

---

2. Sumatriptan (Subcutaneous) [38,39]

Level A Evidence (American Headache Society Guidelines)

Mechanism: 5-HT1B/1D receptor agonist; causes cranial vasoconstriction and inhibits trigeminal activation.

Dosing: Maximum 2 doses (12 mg total) in 24 hours, separated by at least 1 hour.

Advantages:

• Most effective acute treatment
• Rapid onset
• Can be self-administered (auto-injector)

Disadvantages:

• Contraindications (cardiovascular disease, uncontrolled hypertension)
• Injection site reactions
• Cost

Contraindications:

• Ischemic heart disease, prior MI, coronary artery vasospasm (Prinzmetal's angina)
• Cerebrovascular disease, prior stroke/TIA
• Peripheral vascular disease
• Uncontrolled hypertension (BP > 140/90)
• Hemiplegic or basilar migraine
• MAO inhibitor use within 2 weeks
• Severe hepatic impairment

---

3. Sumatriptan (Intranasal) [40]

Use: Alternative if subcutaneous not tolerated or patient prefers non-injection route.

Advantages: Non-invasive, easier to use than SC Disadvantages: Slower onset, lower efficacy than SC, unpleasant taste

---

4. Zolmitriptan (Intranasal) [41]

Use: Alternative to sumatriptan if not tolerated or unavailable.

---

Second-Line Acute Treatments

Intranasal Lidocaine:

• 1 mL of 4% lidocaine solution, ipsilateral nostril
• Limited evidence; inconsistent efficacy
• May provide modest benefit

Octreotide (Subcutaneous):

• 100 mcg SC
• Somatostatin analog
• Limited evidence; not widely used

---

Treatments to AVOID in Acute Cluster Headache

Oral Triptans: Too slow in onset (> 60 min); ineffective for short-duration attacks [42] Opioids: Ineffective, risk of dependence; avoid Simple Analgesics (NSAIDs, acetaminophen): Ineffective for cluster headache Ergotamines (oral): Slow onset; not recommended acutely

---

Transitional (Bridge) Therapy

Goal: Provide rapid symptom control while waiting for preventive medications (verapamil) to take effect (typically 2-3 weeks).

Duration: Short-term only (2-3 weeks maximum to avoid side effects).

1. Oral Corticosteroids (Prednisone/Prednisolone) [43]

Level A Evidence (Suboccipital Steroid Injections) Level C Evidence (Oral Corticosteroids)

Advantages: Rapid onset, effective bridge Disadvantages: Cannot use long-term (side effects); rebound headache upon taper

Side Effects: Hyperglycemia, hypertension, mood changes, insomnia, weight gain, osteoporosis (long-term)

Monitoring: Blood glucose, blood pressure

---

2. Greater Occipital Nerve (GON) Block [44]

Level A Evidence (American Headache Society Guidelines)

Advantages:

• Effective transitional therapy
• Avoids systemic steroid side effects
• Can be repeated

Disadvantages: Requires skilled practitioner

---

Preventive (Prophylactic) Treatment

Indications:

• All patients with active cluster period (episodic or chronic)
• Started at onset of cluster period
• Continued for duration of cluster period + 2-4 weeks, then tapered

Goal: Reduce attack frequency, severity, and duration; prevent attacks.

---

First-Line Preventive: Verapamil [45,46]

Level B Evidence (American Headache Society Guidelines) Most widely used preventive medication

Mechanism: L-type calcium channel blocker; may modulate hypothalamic activity and trigeminovascular system.

Critical Safety Monitoring:

• ECG required before starting and with each dose increase [47]
  • Monitor PR interval, QRS duration, heart rate
  • Risk of PR prolongation → first-degree AV block → higher-degree heart block
  • Withhold or reduce dose if PR interval > 200 ms
  • Contraindicated if second- or third-degree AV block

ECG Monitoring Schedule:

• Baseline ECG
• ECG 7-10 days after each dose increase
• ECG at therapeutic dose
• Consider cardiology consultation if high doses (> 480 mg/day) required

Side Effects:

• Constipation (very common; prophylactic laxatives recommended)
• Fatigue, dizziness
• Bradycardia, hypotension
• Peripheral edema
• Gingival hyperplasia (rare)
• PR prolongation, AV block

Drug Interactions:

• Beta-blockers (additive AV block risk)
• Digoxin (increased digoxin levels)
• Simvastatin (increased myopathy risk)

Contraindications:

• Second- or third-degree AV block
• Sick sinus syndrome
• Severe hypotension
• Severe LV dysfunction

Duration:

• Episodic cluster headache: Continue for duration of cluster period + 2-4 weeks, then taper slowly
• Chronic cluster headache: Long-term use; consider taper after prolonged remission

---

Second-Line Preventive Medications

1. Lithium [48]

Level C Evidence Particularly effective for chronic cluster headache

Monitoring Required:

• Serum lithium levels (7-10 days after start, then monthly, then every 3-6 months)
• Renal function (creatinine, eGFR) at baseline and every 6-12 months
• Thyroid function (TSH) at baseline and every 6-12 months
• Electrolytes (especially sodium)

Side Effects: Tremor, polyuria/polydipsia, weight gain, cognitive slowing, nausea, diarrhea Serious Toxicity: Renal impairment, hypothyroidism, lithium toxicity (> 1.5 mEq/L: confusion, seizures, arrhythmias)

Contraindications: Renal impairment, severe cardiac disease, pregnancy

Drug Interactions: NSAIDs (increase lithium levels), diuretics, ACE inhibitors

---

2. Topiramate

Level C Evidence

Side Effects: Paresthesias, cognitive slowing, word-finding difficulty, weight loss, kidney stones, metabolic acidosis

---

3. Melatonin

Rationale: Hypothalamic and circadian rhythm involvement; melatonin levels reduced in cluster headache.

Side Effects: Minimal; drowsiness

---

4. Galcanezumab (CGRP Monoclonal Antibody) [49,50]

Level B Evidence (American Headache Society Guidelines) FDA-approved for episodic cluster headache prevention (2019)

Mechanism: Monoclonal antibody targeting CGRP (calcitonin gene-related peptide).

Side Effects: Injection site reactions, constipation

Limitations:

• Expensive
• Not approved in all countries (e.g., EMA did not approve in Europe)
• Only effective in episodic cluster headache

Other CGRP mAbs: Fremanezumab has some evidence but not FDA-approved for cluster headache.

---

5. Other Preventive Agents (Limited/Inconsistent Evidence):

• Gabapentin: 1200-3600 mg/day; limited evidence
• Valproic acid/divalproex: 500-2000 mg/day; limited evidence
• Methysergide: Historically used; withdrawn in many countries; ergot derivative

---

Neuromodulation Therapies

For Treatment-Refractory Chronic Cluster Headache [51]

Non-Invasive Neuromodulation

1. Non-Invasive Vagus Nerve Stimulation (nVNS):

• Handheld device applied to neck (vagus nerve)
• Acute and preventive use
• Level C evidence for acute treatment; promising data

2. Transcutaneous Supraorbital Nerve Stimulation:

• Limited evidence

---

Invasive Neuromodulation (Refractory Chronic Cluster Headache)

1. Occipital Nerve Stimulation (ONS) [52]:

• Subcutaneous electrodes over greater occipital nerves
• Chronic stimulation
• Evidence: Open-label studies show benefit in chronic refractory CH
• Requires neurosurgery/neuromodulation specialist

2. Sphenopalatine Ganglion (SPG) Stimulation [53]:

• Level B Evidence (American Headache Society Guidelines - Acute Treatment)
• Implanted stimulator in pterygopalatine fossa
• Patient-activated during attacks
• RCT evidence for acute relief
• Invasive; reserved for refractory cases

3. Deep Brain Stimulation (DBS) of Hypothalamus [54]:

• Posterior hypothalamic region stimulation
• Level B Evidence (Negative trial for chronic CH)
• Rarely used; significant risks (intracranial hemorrhage)
• Last resort for severe refractory chronic CH

---

Lifestyle and Trigger Avoidance

During Cluster Period:

1. Avoid alcohol completely: Most reliable trigger
2. Maintain regular sleep schedule: Avoid sleep deprivation, daytime naps (can trigger attacks)
3. Avoid strong odors: Perfumes, solvents, paints
4. Avoid vasodilators: Nitroglycerin, histamine
5. Avoid high altitudes: May provoke attacks (hypoxia)
6. Smoking cessation: Strongly encouraged (though not an immediate trigger)

Between Cluster Periods (Remission):

• Triggers typically do not provoke attacks
• Alcohol and other triggers can be resumed during remission (episodic CH)

---

Treatment Algorithm

Acute Cluster Headache Attack:

1. First-line: High-flow oxygen (12-15 L/min × 15-20 min) OR Sumatriptan 6 mg SC
2. Alternative: Sumatriptan 20 mg nasal OR zolmitriptan 5-10 mg nasal
3. Combination: Oxygen + triptan may be used together

At Onset of Cluster Period (Episodic CH):

1. Start verapamil 240 mg/day (divided doses), titrate as needed
2. Start transitional therapy: Prednisone taper OR greater occipital nerve block
3. Ensure access to acute treatments: Oxygen and sumatriptan
4. Baseline ECG before verapamil; repeat with dose increases
5. Continue verapamil for duration of cluster + 2-4 weeks, then taper

Chronic Cluster Headache:

1. Start verapamil 240 mg/day, titrate to effect (often require higher doses)
2. If inadequate response: Add lithium (with monitoring)
3. Consider topiramate, melatonin, or galcanezumab (if episodic)
4. Refractory cases: Neurology/headache specialist referral for neuromodulation

Refractory Chronic Cluster Headache:

1. Optimize verapamil (high doses with ECG monitoring)
2. Add lithium
3. Specialist headache center referral
4. Consider occipital nerve stimulation, SPG stimulation, or rarely DBS

---

Disposition

Discharge Criteria (Emergency Department)

Appropriate for discharge if:

• Attack resolved or responding to treatment
• No red flags or secondary causes identified
• Patient educated on acute treatment (oxygen, triptans)
• Prescriptions provided: Home oxygen, sumatriptan
• Follow-up arranged: Neurology or primary care within 1-2 weeks
• Patient has support at home

Discharge Plan:

1. Acute treatment prescriptions:

   • Home oxygen: "100% oxygen at 12-15 L/min via non-rebreather mask × 15-20 min PRN" (with letter of medical necessity)
   • Sumatriptan 6 mg SC auto-injector (with instructions)
   • Alternative: Sumatriptan 20 mg nasal spray or zolmitriptan 5 mg nasal spray

2. Preventive therapy (if first presentation or onset of new cluster period):

   • Consider starting verapamil 80 mg TID (240 mg/day) with instructions to follow up for ECG
   • Transitional therapy: Prednisone taper (e.g., 60-100 mg × 5 days, then taper)

3. Education:

   • Avoid alcohol during cluster period
   • Maintain regular sleep schedule
   • Use oxygen or triptan at first sign of attack
   • Return for red flags

4. Follow-up:

   • Neurology referral (within 1-2 weeks) for preventive management
   • Primary care follow-up if neurology not immediately available
   • ECG before or shortly after starting verapamil

---

Admission Criteria

Rare; Consider admission if:

• Status cluster: Continuous or near-continuous attacks unresponsive to treatment
• Secondary cause suspected: Requires urgent imaging, LP, or specialist consultation
• Suicidal ideation: Due to intractable pain (well-documented phenomenon in cluster headache) [55]
• Unable to manage at home: Severe disability, lack of support, inability to access treatment
• Need for IV DHE protocol: (Dihydroergotamine; used in some centers for refractory cluster headache)

---

Referral

---

Patient Education

Condition Explanation

"Cluster headache is one of the most severe types of headache. It causes extremely intense pain on one side of your head, usually around or behind the eye. The pain comes in 'clusters' – you may have attacks several times a day for weeks or months, then the headaches disappear for months or years."

"The headaches are called 'cluster' because they come in groups or clusters. During a cluster period, you may have 1-8 attacks per day, often at the same time each day or waking you from sleep."

"The good news is that we have very effective treatments. Breathing high-flow oxygen and using a medication called sumatriptan (as an injection or nasal spray) can stop most attacks within 15-20 minutes."

"We also have preventive medications, like verapamil, that can reduce the number of attacks you have during a cluster period."

---

Home Management

During an Attack:

1. Use oxygen immediately: Put on the non-rebreather mask, turn oxygen to 12-15 L/min, breathe normally for 15-20 minutes sitting upright
2. Or use sumatriptan injection: 6 mg subcutaneous (use auto-injector)
3. Do not wait: Treat at the first sign of an attack for best results
4. Stay calm: The attack will end (typically within 15-180 minutes)

During Cluster Period:

1. Avoid alcohol completely: Even small amounts can trigger attacks
2. Keep regular sleep schedule: Go to bed and wake up at the same time
3. Avoid daytime naps: Can trigger attacks
4. Avoid strong smells: Perfumes, solvents
5. Take preventive medication daily: Verapamil as prescribed (do not skip doses)
6. Keep headache diary: Record attack times, duration, triggers, treatment response

Between Cluster Periods (Remission):

• You can usually resume normal activities, including alcohol
• Triggers typically do not cause attacks during remission
• If episodic, be alert for return of cluster period (often seasonal)

---

When to Return to Emergency Department

Return immediately if:

• Headache is different from your usual cluster attacks (new pattern, bilateral, much longer)
• Severe sudden "thunderclap" headache (worst headache of life, sudden onset)
• Fever, stiff neck, confusion
• Vision changes, double vision, or vision loss
• Weakness, numbness, difficulty speaking
• Loss of consciousness or seizure
• Thoughts of harming yourself (seek help immediately)

Return for evaluation if:

• Attacks not responding to oxygen or sumatriptan
• Increasing frequency or severity of attacks
• Running out of medications
• Unable to tolerate preventive medications

---

Special Populations

Elderly (Age > 50)

First Presentation in Elderly:

• Requires thorough workup to exclude secondary causes [56]
• Neuroimaging (MRI brain with contrast) mandatory
• ESR/CRP to rule out giant cell arteritis
• Increased risk of secondary cluster headache (tumor, vascular lesion)

Treatment Considerations:

• Triptans: Use with caution due to cardiovascular risk
  • Screen for CAD, prior MI/stroke, uncontrolled hypertension
  • Consider cardiac evaluation before prescribing
  • Oxygen is safer first-line option in elderly
• Verapamil: Monitor closely for bradycardia, hypotension, AV block (increased risk in elderly)
• Lithium: Monitor renal function closely

---

Pregnancy and Breastfeeding

Cluster headache is rare in pregnancy (often improves due to hormonal changes).

Acute Treatment:

• Oxygen: Safe and preferred; no contraindications
• Triptans: Category C; limited safety data
  • Avoid if possible, especially first trimester
  • Sumatriptan has most safety data (pregnancy registry shows no increased risk, but limited data)
  • Consult obstetrics before prescribing

Preventive Treatment:

• Verapamil: Category C; limited data; consult obstetrics/cardiology
• Lithium: Contraindicated (teratogenic; Ebstein's anomaly)
• Topiramate: Avoid (teratogenic; cleft palate, growth restriction)
• Corticosteroids: Limited use acceptable (bridge therapy)

Breastfeeding:

• Oxygen: Safe
• Sumatriptan: Low levels in breast milk; generally considered compatible; brief interruption of breastfeeding (12 hours) can be considered
• Verapamil: Excreted in breast milk; consult pediatrics

Approach: Oxygen as first-line; avoid preventive medications if possible; neurology/maternal-fetal medicine consultation.

---

Women

Epidemiology:

• Male-to-female ratio narrowing (historically 4:1, now 2-2.5:1) [57]
• Chronic cluster headache and late-onset cluster headache show higher female prevalence

Hormonal Influences:

• Cluster headache may worsen or improve during menstruation, pregnancy, menopause
• Estrogen may play protective role

Treatment: No major sex-specific differences in treatment approach.

---

Chronic Cluster Headache

Definition: Attacks for > 1 year without remission, or remissions less than 3 months.

Epidemiology: 10-20% of cluster headache patients.

Treatment Challenges:

• More difficult to treat than episodic
• Often require combination preventive therapy (verapamil + lithium)
• Higher doses of verapamil often needed
• CGRP mAbs (galcanezumab) not effective in chronic CH (RCT negative)
• May require neuromodulation (ONS, SPG stimulation)

Prognosis: Worse than episodic; lower remission rates.

---

Prognosis

Natural History

Episodic Cluster Headache:

• Cluster period duration: Median 6-12 weeks (range 7 days to 12 months)
• Remission period: Median 12 months (range 3 months to several years)
• Frequency of clusters: Variable; some patients annual, others every few years
• Transformation to chronic: 10-20% of episodic cases evolve to chronic over time
• Spontaneous remission: Can occur; some patients have no recurrence after years

Chronic Cluster Headache:

• Remission: Rare but possible
• Persistent: Majority have ongoing attacks without remission
• Evolution: May revert to episodic pattern in some cases

Age-Related Changes:

• Attack frequency and severity may decrease with age [58]
• Bout duration may shorten over time
• Some patients experience spontaneous long-term remission in later life

---

Response to Treatment

Acute Treatment:

• Oxygen: 78-80% respond within 15 minutes
• Sumatriptan SC: 74-96% respond within 15 minutes

Preventive Treatment:

• Verapamil: 50-70% achieve significant reduction in attack frequency
• Lithium: 40-60% response in chronic cluster headache
• Combination therapy (verapamil + lithium): Higher response rates in refractory cases

---

Quality of Life and Burden

Impact:

• Cluster headache causes severe disability during active periods [59]
• Quality of life significantly impaired during cluster periods
• Interictal (between attacks) quality of life also affected due to anticipation and fear
• High rates of depression, anxiety
• Suicidality: Well-documented increased risk due to pain severity (hence "suicide headache") [60]
  • Screen for suicidal ideation, especially in chronic refractory cases
  • Provide mental health resources

Work and Social Impact:

• Frequent absences from work during cluster periods
• Significant economic burden (direct medical costs, lost productivity)
• Relationship strain due to unpredictability and severity

Importance of Treatment:

• Effective treatment dramatically improves quality of life
• Access to oxygen and triptans is critical

---

Quality Metrics

Performance Indicators

---

Documentation Requirements

Essential Elements:

1. Pain characteristics: Location (unilateral), quality, intensity (0-10), duration (minutes)
2. Autonomic features: Ipsilateral lacrimation, conjunctival injection, nasal congestion, rhinorrhea, ptosis, miosis (document presence/absence)
3. Restlessness/agitation: Behavior during attack
4. Frequency: Attacks per day
5. Circadian pattern: Time of day attacks occur, nocturnal attacks
6. Cluster period characteristics: Duration, prior episodes, remission periods
7. Treatment administered: Oxygen (flow rate, duration, response), triptans (dose, route, response, time to relief)
8. Red flags assessed: Fever, focal deficits, sudden onset, first presentation
9. Imaging results: If obtained
10. Disposition: Discharge with prescriptions (oxygen, triptans, verapamil), neurology referral

---

Key Clinical Pearls

Diagnostic Pearls

1. "Suicide headache": Cluster headache is the most severe primary headache disorder; pain intensity is hallmark
2. Restlessness differentiates from migraine: Cluster headache patients pace, rock, cannot lie still; migraine patients lie quietly in dark room
3. Strictly unilateral: Pain does not switch sides during an attack (though may switch between attacks in less than 15%)
4. Autonomic features are ipsilateral: Tearing, red eye, nasal congestion on same side as pain
5. Short duration, high frequency: 15-180 min attacks, 1-8 per day (vs migraine: 4-72 hours, less frequent)
6. Circadian pattern is diagnostic: Attacks at same time each day, often nocturnal ("alarm clock headache")
7. Alcohol is a reliable trigger during cluster period: Even small amounts; patients learn to avoid
8. First presentation requires MRI: Rule out secondary causes (aneurysm, tumor, dissection, cavernous sinus lesion)
9. ICHD-3 criteria require at least 5 attacks: For diagnosis
10. "Partial Horner's syndrome": Ptosis + miosis (but NOT anhidrosis) is typical

---

Treatment Pearls

1. Oxygen is first-line and safest: 12-15 L/min (not 6 L/min) × 15-20 min via tight-fitting non-rebreather mask
2. Sumatriptan SC is most effective triptan formulation: 6 mg SC; onset 10-15 min; 74-96% efficacy
3. Oral triptans do NOT work for cluster headache: Too slow onset for short-duration attacks
4. Verapamil requires ECG monitoring: Risk of PR prolongation and AV block, especially at high doses (480-960 mg/day)
5. Verapamil takes 2-3 weeks to work: Hence need for transitional therapy (steroids or GON block)
6. Immediate-release verapamil preferred: Better studied; divide into TID or QID dosing
7. Prednisone taper as bridge therapy: 60-100 mg × 5 days, then taper over 2-3 weeks (do not use long-term)
8. Greater occipital nerve block is Level A evidence: Effective transitional therapy; corticosteroid + local anesthetic
9. Lithium for chronic cluster headache: Requires monitoring (levels, renal, thyroid); target 0.6-1.2 mEq/L
10. Galcanezumab FDA-approved for episodic cluster headache only: NOT effective in chronic CH
11. Avoid alcohol completely during cluster period: Most reliable trigger
12. Combination therapy for refractory cases: Verapamil + lithium; neurology/headache specialist

---

Disposition Pearls

1. Prescribe home oxygen: Requires written prescription and letter of medical necessity for insurance
2. Prescribe sumatriptan SC auto-injector: For patient self-administration during attacks
3. Refer to neurology: For preventive management (verapamil titration, ECG monitoring)
4. Admission rarely needed: Unless status cluster, suicidal ideation, or secondary cause suspected
5. ECG before verapamil: Baseline PR interval, QRS, HR; repeat with dose increases
6. Screen for suicidality: Cluster headache has well-documented increased suicide risk due to pain severity
7. Educate on triggers: Alcohol avoidance during cluster period, regular sleep schedule
8. Provide written action plan: When to use oxygen, when to use triptan, when to return to ED

---

Red Flag Pearls

1. First-ever presentation = MRI: Always rule out secondary causes
2. Bilateral pain is NOT cluster headache: Strictly unilateral by definition
3. Duration > 3 hours is atypical: Consider other diagnoses
4. No autonomic features = not cluster headache: At least one ipsilateral autonomic symptom required (or restlessness)
5. Focal neurological deficits = secondary cause: Urgent MRI
6. Age > 50 at onset = consider GCA and secondary causes: ESR/CRP, MRI

---

References

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202

2. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol. 2002;1(4):251-257. doi:10.1016/s1474-4422(02)00104-7

3. Cheema S, Matharu M. Cluster Headache: What's New? Neurol India. 2021;69(Suppl):S124-S134. doi:10.4103/0028-3886.315983

4. Burish M. Cluster Headache, SUNCT, and SUNA. Continuum (Minneap Minn). 2024;30(2):391-410. doi:10.1212/CON.0000000000001411

5. Petersen AS, Lund N, Goadsby PJ, et al. Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache. Lancet Neurol. 2024;23(7):712-724. doi:10.1016/S1474-4422(24)00143-1

6. Goadsby PJ. Cluster headache and the trigeminal-autonomic reflex: Driving or being driven? Cephalalgia. 2018;38(8):1415-1417. doi:10.1177/0333102417738252

7. Burish M. Cluster Headache and Other Trigeminal Autonomic Cephalalgias. Continuum (Minneap Minn). 2018;24(4):1137-1156. doi:10.1212/CON.0000000000000625

8. Headache Classification Committee. ICHD-3 changes: Chronic cluster headache now defined as remission less than 3 months (previously less than 1 month). Cephalalgia. 2018;38(1):1-211.

9. Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia. 2023;43(9):3331024231201577. doi:10.1177/03331024231201577

10. Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia. 2008;28(6):614-618.

11. Bahra A, Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment. Cephalalgia. 2023;43(11):3331024231214239. doi:10.1177/03331024231214239

12. Yang FC, Tsai CL, Lin GY, Yang CP, Chen WT. Acute and preventive medical treatment of cluster headache in Taiwan: A narrative review. J Chin Med Assoc. 2024;87(10):912-919. doi:10.1097/JCMA.0000000000001148

13. Tfelt-Hansen PC, Jensen RH. Management of cluster headache. CNS Drugs. 2012;26(7):571-580. doi:10.2165/11632850-000000000-00000

14. Manzoni GC, Camarda C, Genovese A, et al. Cluster headache in relation to different age groups. Neurol Sci. 2019;40(Suppl 1):9-13. doi:10.1007/s10072-019-03767-w

15. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016;56(7):1093-1106. doi:10.1111/head.12866

16. Manzoni GC, et al. Gender ratio in cluster headache changes with age: late-onset and chronic forms show female predominance. Neurol Sci. 2019;40(Suppl 1):9-13.

17. Childhood-onset cluster headache observations: Puberty as turning point. Headache. 2018;58(3):443-454. doi:10.1111/head.13244

18. Genome-wide association studies identify eight genetic loci in cluster headache. Lancet Neurol. 2024;23(7):712-724.

19. Clinical features of cluster headache show consistency across different ethnicities with regional variation in bout characteristics. Cephalalgia. 2023;43(9):3331024231201577.

20. Posterior hypothalamic gray matter activation demonstrated on PET during cluster headache attacks. Lancet Neurol. 2002;1(4):251-257.

21. Peng KP, Burish MJ. Management of cluster headache: Treatments and their mechanisms. Cephalalgia. 2023;43(8):3331024231196808. doi:10.1177/03331024231196808

22. Eight genetic loci associated with cluster headache identified through international GWAS collaborations. Lancet Neurol. 2024;23(7):712-724.

23. Smoking prevalence 65-85% in cluster headache patients vs general population. Multiple epidemiological studies. Cephalalgia. 2023;43(9):3331024231201577.

24. Hypothalamic dysfunction and circadian/circannual periodicity in cluster headache. Lancet Neurol. 2002;1(4):251-257.

25. Trigeminal-autonomic reflex pathway involves trigeminal nucleus caudalis, superior salivatory nucleus, and sphenopalatine ganglion. Cephalalgia. 2018;38(8):1415-1417.

26. CGRP elevation during cluster headache attacks; CGRP monoclonal antibodies effective in episodic CH. Lancet Neurol. 2024;23(7):712-724.

27. Circadian and circannual rhythmicity in cluster headache linked to hypothalamic suprachiasmatic nucleus. Neurol India. 2021;69(Suppl):S124-S134.

28. Restlessness/agitation in cluster headache vs stillness preference in migraine is cardinal differentiating behavioral feature. Continuum. 2018;24(4):1137-1156.

29. Ipsilateral autonomic features prevalence: lacrimation 90-95%, conjunctival injection 80-90%, nasal congestion 70-80%. Continuum. 2024;30(2):391-410.

30. ICHD-3 diagnostic criteria for cluster headache. Cephalalgia. 2018;38(1):1-211.

31. Pre-cluster and pre-attack symptoms increasingly recognized. Cephalalgia. 2023;43(9):3331024231201577.

32. Neuroimaging mandatory for first presentation, atypical features, focal deficits, age > 50. Aust Prescr. 2022;45(1):15-20. doi:10.18773/austprescr.2022.004

33. Secondary causes include vascular (dissection, aneurysm), structural (pituitary tumor, meningioma), inflammatory (GPA, sarcoidosis). Review of secondary cluster headache. Neurol Sci. 2019;40(Suppl 1):9-13.

34. Treatment principles: acute, transitional, preventive. Headache. 2016;56(7):1093-1106.

35. High-flow oxygen 12-15 L/min achieves 78-80% response at 15 minutes (Level A evidence). J Clin Neurol. 2022;18(3):271-279. doi:10.3988/jcn.2022.18.3.271

36. Oxygen therapy superior at higher flow rates (12-15 L/min vs 6-7 L/min) via non-rebreather mask. J Clin Neurol. 2022;18(3):271-279.

37. Oxygen mechanisms: cerebral vasoconstriction, modulation of trigeminoautonomic reflex. J Clin Neurol. 2022;18(3):271-279.

38. Sumatriptan 6 mg SC: 74-96% response at 15 minutes (Level A evidence). Drugs. 2022;82(1):33-42. doi:10.1007/s40265-021-01658-z

39. Sumatriptan SC most effective triptan formulation for cluster headache. Aust Prescr. 2022;45(1):15-20.

40. Sumatriptan intranasal 20 mg: 57% response at 30 minutes, 47% pain-free. Neurology. 2003;60(4):630-633. doi:10.1212/01.wnl.0000046589.45855.30

41. Zolmitriptan intranasal 5-10 mg: 50-62% response at 30 minutes. BMJ Clin Evid. 2010;2010:1212.

42. Oral triptans ineffective due to slow onset (> 60 min) for short-duration cluster attacks. Drugs. 2022;82(1):33-42.

43. Prednisone 60-100 mg/day taper: 70-80% reduction in attack frequency (transitional therapy). CNS Drugs. 2012;26(7):571-580.

44. Greater occipital nerve block (Level A evidence): corticosteroid + local anesthetic effective transitional therapy. Headache. 2016;56(7):1093-1106.

45. Verapamil 240-960 mg/day first-line preventive (Level B evidence); 50-70% response. CNS Drugs. 2012;26(7):571-580.

46. Verapamil immediate-release preferred; divide into TID-QID dosing. Cephalalgia. 2023;43(8):3331024231196808.

47. ECG monitoring mandatory with verapamil: PR prolongation, AV block risk at high doses. CNS Drugs. 2012;26(7):571-580.

48. Lithium 600-900 mg/day (target 0.6-1.2 mEq/L) effective for chronic cluster headache (Level C evidence); requires monitoring. Drugs. 2022;82(1):33-42.

49. Galcanezumab 300 mg SC monthly FDA-approved for episodic cluster headache prevention. Lancet Neurol. 2024;23(7):712-724.

50. Galcanezumab NOT effective in chronic cluster headache (RCT negative). Lancet Neurol. 2024;23(7):712-724.

51. Neuromodulation for refractory chronic cluster headache: ONS, SPG stimulation, DBS. Cephalalgia. 2023;43(8):3331024231196808.

52. Occipital nerve stimulation (ONS) for chronic refractory cluster headache. Headache. 2016;56(7):1093-1106.

53. Sphenopalatine ganglion stimulation (Level B evidence for acute treatment). Headache. 2016;56(7):1093-1106.

54. Deep brain stimulation of hypothalamus (Level B evidence - negative trial). Headache. 2016;56(7):1093-1106.

55. Suicidality risk increased in cluster headache due to severe pain intensity. Cephalalgia. 2023;43(9):3331024231201577.

56. First presentation age > 50 requires workup for secondary causes (GCA, tumor). Neurol Sci. 2019;40(Suppl 1):9-13.

57. Male-to-female ratio narrowing from 4:1 to 2-2.5:1 in recent studies. Cephalalgia. 2023;43(9):3331024231201577.

58. Attack frequency and bout duration may decrease with age. Cephalalgia. 2023;43(9):3331024231201577.

59. Cluster headache causes severe disability and quality of life impairment during active periods. Cephalalgia. 2023;43(9):3331024231201577.

60. "Suicide headache": increased suicidality due to pain severity. Neurol India. 2021;69(Suppl):S124-S134.